Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer
- PMID: 38677579
- DOI: 10.1016/j.jep.2024.118265
Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer
Abstract
Ethnopharmacological relevance: Traditional Chinese Medicines (TCMs) have emerged as a promising complementary therapy in the management of prostate cancer (PCa), particularly in addressing resistance to Docetaxel (DTX) chemotherapy.
Aim of the review: This review aims to elucidate the mechanisms underlying the development of resistance to DTX in PCa and explore the innovative approach of integrating TCMs in PCa treatment to overcome this resistance. Key areas of investigation include alterations in microtubule proteins, androgen receptor and androgen receptor splice variant 7, ERG rearrangement, drug efflux mechanisms, cancer stem cells, centrosome clustering, upregulation of the PI3K/AKT signaling pathway, enhanced DNA damage repair capability, and the involvement of neurotrophin receptor 1/protein kinase C.
Materials and methods: With "Prostate cancer", "Docetaxel", "Docetaxel resistance", "Natural compounds", "Traditional Chinese medicine", "Traditional Chinese medicine compound", "Medicinal plants" as the main keywords, PubMed, Web of Science and other online search engines were used for literature retrieval.
Results: Our findings underscore the intricate interplay of molecular alterations that collectively contribute to the resistance of PCa cells to DTX. Moreover, we highlight the potential of TCMs as a promising complementary therapy, showcasing their ability to counteract DTX resistance and enhance therapeutic efficacy.
Conclusion: The integration of TCMs in PCa treatment emerges as an innovative approach with significant potential to overcome DTX resistance. This review not only provides insights into the mechanisms of resistance but also presents new prospects for improving the clinical outcomes of patients with PCa undergoing DTX therapy. The comprehensive understanding of these mechanisms lays the foundation for future research and the development of more effective therapeutic interventions.
Keywords: Docetaxel; Prostate cancer; Resistance mechanisms; Reversal effects; Traditional Chinese medicines.
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest We confirm that this manuscript has not been published elsewhere and is not under consideration by another journal. All authors have approved the manuscript and agree with submission to your esteemed journal.
Similar articles
-
In vitro modulation the Notch pathway by piperine: A therapeutic strategy for docetaxel-resistant and non-resistant prostate cancer.Chem Biol Drug Des. 2024 Jun;103(6):e14562. doi: 10.1111/cbdd.14562. Chem Biol Drug Des. 2024. PMID: 38898371
-
Cynanchum wallichii Wight and CW1 reversed docetaxel resistance effects by inhibiting P-gp and promoting PI3K/Akt-mediated apoptosis in prostate cancer.Biochem Pharmacol. 2025 Feb;232:116749. doi: 10.1016/j.bcp.2025.116749. Epub 2025 Jan 7. Biochem Pharmacol. 2025. PMID: 39788386
-
Polyphyllin VII Enhances the Sensitivity of Prostate Cancer Cells to Docetaxel by Promoting Mitochondrial Dysfunction and Inducing Ferroptosis.Chem Biol Drug Des. 2025 Feb;105(2):e70053. doi: 10.1111/cbdd.70053. Chem Biol Drug Des. 2025. PMID: 39871642
-
Molecular mechanisms of docetaxel resistance in prostate cancer.Cancer Drug Resist. 2020 Aug 21;3(4):676-685. doi: 10.20517/cdr.2020.37. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582222 Free PMC article. Review.
-
A review on the microtubule inhibitory effects of active ingredients extracted from TCMs and ethnic medicines in cancer treatment.J Ethnopharmacol. 2025 Jun 26;350:120034. doi: 10.1016/j.jep.2025.120034. Epub 2025 May 30. J Ethnopharmacol. 2025. PMID: 40451492 Review.
Cited by
-
Targeting the cuproptosis‑associated gene COL22A1 in glioblastoma using EMD‑1204831 and kaempferol.Int J Oncol. 2025 May;66(5):38. doi: 10.3892/ijo.2025.5744. Epub 2025 Apr 17. Int J Oncol. 2025. PMID: 40242972 Free PMC article.
-
Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.Front Pharmacol. 2025 Feb 17;16:1504618. doi: 10.3389/fphar.2025.1504618. eCollection 2025. Front Pharmacol. 2025. PMID: 40034825 Free PMC article. Review.
-
Inhibition of EREG/ErbB/ERK by Astragaloside IV reversed taxol-resistance of non-small cell lung cancer through attenuation of stemness via TGFβ and Hedgehog signal pathway.Cell Oncol (Dordr). 2024 Dec;47(6):2201-2215. doi: 10.1007/s13402-024-00999-7. Epub 2024 Oct 7. Cell Oncol (Dordr). 2024. PMID: 39373858
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials